Identification and validation of microRNAs that synergize with miR-34a – a basis for combinatorial microRNA therapeutics

References

• Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell. 1993;75:855–862.
   PubMed Web of Science ®Google Scholar
• Reinhart BJ, Slack FJ, Basson M, et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 2000;403:901–906.
   PubMed Web of Science ®Google Scholar
• Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75:843–854.
   PubMed Web of Science ®Google Scholar
• Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ. 2010;17:193–199.
   PubMed Web of Science ®Google Scholar
• Gallardo E, Navarro A, Viñolas N, et al. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis. 2009;30:1903–1909.
   PubMed Web of Science ®Google Scholar
• Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857–866.
   PubMed Web of Science ®Google Scholar
• Bommer GT, Gerin I, Feng Y, et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol. 2007;17:1298–1307.
   PubMed Web of Science ®Google Scholar
• O’Donnell KA, Wentzel EA, Zeller KI, et al. c-Myc-regulated microRNAs modulate E2F1 expression. Nature. 2005;435:839–843.
   PubMed Web of Science ®Google Scholar
• Lodygin D, Tarasov V, Epanchintsev A, et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle. 2008;7:2591–2600.
   PubMed Web of Science ®Google Scholar
• Saito Y, Liang G, Egger G, et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell. 2006;9:435–443.
   PubMed Web of Science ®Google Scholar
• Melo SA, Moutinho C, Ropero S, et al. A genetic defect in Exportin-5 traps precursor MicroRNAs in the nucleus of cancer cells. Cancer Cell. 2010;18:303–315.
   PubMed Web of Science ®Google Scholar
• Hill DA, Ivanovich J, Priest JR, et al. DICER1 mutations in Familial pleuropulmonary blastoma. Science. 2009;325:965.
   PubMed Web of Science ®Google Scholar
• Piskounova E, Polytarchou C, Thornton JE, et al. Lin28A and Lin28B inhibit let-7 microRNA biogenesis by distinct mechanisms. Cell. 2011;147:1066–1079.
   PubMed Web of Science ®Google Scholar
• Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA. 2004;101:2999–3004.
   PubMed Web of Science ®Google Scholar
• Toyota M, Suzuki H, Sasaki Y, et al. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res. 2008;68:4123–4132.
   PubMed Web of Science ®Google Scholar
• Chang T-C, Wentzel EA, Kent OA, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 2007;26:745–752.
   PubMed Web of Science ®Google Scholar
• He X, He L, Hannon GJ. The guardian’s little helper: microRNAs in the p53 tumor suppressor network. Cancer Res. 2007;67:11099–11101.
   PubMed Web of Science ®Google Scholar
• Raver-Shapira N, Marciano E, Meiri E, et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell. 2007;26:731–743.
   PubMed Web of Science ®Google Scholar
• Tarasov V, Jung P, Verdoodt B, et al. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle. 2007;6:1586–1593.
   PubMed Web of Science ®Google Scholar
• Kim M, Kasinski AL, Slack FJ. MicroRNA therapeutics in preclinical cancer models. Lancet Oncol. 2011;12:319–321.
   PubMed Web of Science ®Google Scholar
• Kasinski AL, Slack FJ. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer. 2011;11:849–864.
   PubMed Web of Science ®Google Scholar
• Kasinski AL, Kelnar K, Stahlhut C, et al. A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer. Oncogene. 2015;34:3547–3555.
   PubMed Web of Science ®Google Scholar
• Kasinski AL, Slack FJ. miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma. Cancer Res. 2012;72:5576–5587.
   PubMed Web of Science ®Google Scholar
• Trang P, Wiggins JF, Daige CL, et al. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther. 2011;19:1116–1122.
   PubMed Web of Science ®Google Scholar
• Orellana EA, Tenneti S, Rangasamy L, et al. FolamiRs: ligand-targeted, vehicle-free delivery of microRNAs for the treatment of cancer. Sci Transl Med. 2017;9:eaam9327.
   PubMed Web of Science ®Google Scholar
• Xue W, Dahlman JE, Tammela T, et al. Small RNA combination therapy for lung cancer. Proc Nat Acad Sci. 2014;111:E3553–61.
   PubMed Web of Science ®Google Scholar
• Myoung SS, Kasinski AL. CHAPTER 14: strategies for safe and targeted delivery of microRNA therapeutics. In: microRNAs in diseases and disorders. Royal Society of Chemistry 2019. p. 386–415.
   Google Scholar
• Bader AG. miR-34 – a microRNA replacement therapy is headed to the clinic. Front Genet. 2012;3:120.
   PubMedGoogle Scholar
• Bouchie A. First microRNA mimic enters clinic. Nat Biotechnol. 2013;31:577.
   PubMed Web of Science ®Google Scholar
• Stahlhut C, Cycle FSC. Combinatorial action of microRNAs let-7 and miR-34 effectively synergizes with erlotinib to suppress non-small cell lung cancer cell proliferation. Cell Cycle. 2015;14:2171–2180.
   PubMed Web of Science ®Google Scholar
• Zhang L, Yang X, Lv Y, et al. Cytosolic co-delivery of miRNA-34a and docetaxel with core-shell nanocarriers via caveolae-mediated pathway for the treatment of metastatic breast cancer. Sci Rep. 2017;7:46186.
   PubMed Web of Science ®Google Scholar
• Karaayvaz M, Zhai H, Ju J. miR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer. Cell Death Dis. 2013;4:e659.
   PubMed Web of Science ®Google Scholar
• Deng X, Cao M, Zhang J, et al. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer. Biomaterials. 2014;35:4333–4344.
   PubMed Web of Science ®Google Scholar
• Shi S, Han L, Deng L, et al. Dual drugs (microRNA-34a and paclitaxel)-loaded functional solid lipid nanoparticles for synergistic cancer cell suppression. J Control Release. 2014;194:228–237.
   PubMed Web of Science ®Google Scholar
• Lewis BP, Shih I-H, Jones-Rhoades MW, et al. Prediction of mammalian microRNA targets. Cell. 2003;115:787–798.
   PubMed Web of Science ®Google Scholar
• Lytle JR, Yario TA, Steitz JA. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5′ UTR as in the 3′ UTR. Proc Natl Acad Sci USA. 2007;104:9667–9672.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359:1367–1380.
   PubMed Web of Science ®Google Scholar
• Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nature Reviews Cancer. 2009;9:749-758.
   Google Scholar
• Nigro JM, Baker SJ, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature. 1989;342:705–708.
   PubMed Web of Science ®Google Scholar
• Orellana EA, Abdelaal AM, Rangasamy L, et al. Enhancing microRNA activity through increased endosomal release mediated by nigericin. Mol Ther Nucleic Acids. 2019;16:505–518.
   PubMedGoogle Scholar
• Orellana E, Kasinski A. Sulforhodamine B (SRB) assay in cell culture to investigate cell proliferation. Bio-Protocol. 2016;6(21).
   Google Scholar
• Slinker BK. The statistics of synergism. J Mol Cell Cardiol. 1998;30:723–731.
   PubMed Web of Science ®Google Scholar
• Foucquier J, Guedj M. Analysis of drug combinations: current methodological landscape. Pharmacol Res Perspect. 2015;3:e00149.
   PubMed Web of Science ®Google Scholar
• Chou T-C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58:621–681.
   PubMed Web of Science ®Google Scholar
• Agarwal V, Bell GW, Nam JW, et al. Predicting effective microRNA target sites in mammalian mRNAs. Elife. 2015;4:101.
   Web of Science ®Google Scholar
• Wong N, Wang X. miRDB: an online resource for microRNA target prediction and functional annotations. Nucleic Acids Res. 2015;43:D146–52.
   PubMed Web of Science ®Google Scholar
• Kehl T, Backes C, Kern F, et al. About miRNAs, miRNA seeds, target genes and target pathways. Oncotarget. 2017;8:107167–107175.
   PubMedGoogle Scholar
• Backes C, Kehl T, Stöckel D, et al. miRPathDB: a new dictionary on microRNAs and target pathways. Nucleic Acids Res. 2017;45:D90–6.
   PubMed Web of Science ®Google Scholar
• Porayette P, Gallego MJ, Kaltcheva MM, et al. Differential processing of amyloid-beta precursor protein directs human embryonic stem cell proliferation and differentiation into neuronal precursor cells. J Biol Chem. 2009;284:23806–23817.
   PubMed Web of Science ®Google Scholar
• Kloet DEA, Polderman PE, Eijkelenboom A, et al. FOXO target gene CTDSP2 regulates cell cycle progression through Ras and p21(Cip1/Waf1). Biochem J. 2015;469:289–298.
   PubMed Web of Science ®Google Scholar
• Winans S, Flynn A, Malhotra S, et al. Integration of ALV into CTDSPL and CTDSPL2 genes in B-cell lymphomas promotes cell immortalization, migration and survival. Oncotarget. 2017;8:57302–57315.
   PubMedGoogle Scholar
• Mittal S, Aslam A, Doidge R, et al. The Ccr4a (CNOT6) and Ccr4b (CNOT6L) deadenylase subunits of the human Ccr4-not complex contribute to the prevention of cell death and senescence. Mol Biol Cell. 2011;22:748–758.
   PubMed Web of Science ®Google Scholar
• Demidyuk IV, Shubin AV, Gasanov EV, et al. Alterations in gene expression of proprotein convertases in human lung cancer have a limited number of scenarios. PLoS One. 2013;8:e55752.
   PubMed Web of Science ®Google Scholar
• Deb S, Xu H, Tuynman J, et al. RAD21 cohesin overexpression is a prognostic and predictive marker exacerbating poor prognosis in KRAS mutant colorectal carcinomas. Br J Cancer. 2014;110:1606–1613.
   PubMed Web of Science ®Google Scholar
• Supernat A, Lapińska-Szumczyk S, Sawicki S, et al. Deregulation of RAD21 and RUNX1 expression in endometrial cancer. Oncol Lett. 2012;4:727–732.
   PubMed Web of Science ®Google Scholar
• Atienza JM, Roth RB, Rosette C, et al. Suppression of RAD21 gene expression decreases cell growth and enhances cytotoxicity of etoposide and bleomycin in human breast cancer cells. Mol Cancer Ther. 2005;4:361–368.
   PubMed Web of Science ®Google Scholar
• Pinho AV, Van Bulck M, Chantrill L, et al. ROBO2 is a stroma suppressor gene in the pancreas and acts via TGF-β signalling. Nat Commun. 2018;9:5083.
   PubMed Web of Science ®Google Scholar
• Hsu T-I, Wang M-C, Chen S-Y, et al. Sp1 expression regulates lung tumor progression. Oncogene. 2012;31:3973–3988.
   PubMed Web of Science ®Google Scholar
• Beishline K, Azizkhan-Clifford J. Sp1 and the ‘hallmarks of cancer’. Febs J. 2015;282:224–258.
   PubMed Web of Science ®Google Scholar
• Goffin V. Prolactin receptor targeting in breast and prostate cancers: new insights into an old challenge. Pharmacol Ther. 2017;179:111–126.
   PubMed Web of Science ®Google Scholar
• Wang S-M, Tie J, Wang W-L, et al. POU2F2-oriented network promotes human gastric cancer metastasis. Gut. 2016;65:1427–1438.
   PubMed Web of Science ®Google Scholar
• Hodson DJ, Shaffer AL, Xiao W, et al. Regulation of normal B-cell differentiation and malignant B-cell survival by OCT2. Proc Nat Acad Sci. 2016;113:E2039–46.
   PubMed Web of Science ®Google Scholar
• Du P, Wang S, Tang X, et al. Reduced expression of Metastasis Suppressor-1 (MTSS1) accelerates progression of human bladder uroepithelium cell carcinoma. Anticancer Res. 2017;37:4499–4505.
   PubMed Web of Science ®Google Scholar
• Xie F, Ye L, Ta M, et al. MTSS1: a multifunctional protein and its role in cancer invasion and metastasis. Front Biosci Schol. 2011;3:S:621–631.
   Google Scholar